智通财经APP讯,百利天恒(688506.SH)公告,公司的合作伙伴百时美施贵宝收到美国食品药品监督管理局(“FDA”)的通知,BL-B01D1联合用药项目用于治疗晚期实体瘤的1/2a期临床试验申请已获得FDA许可。BL-B01D1是全球首创也是唯一进入临床阶段的靶向EGFR×HER3的双抗ADC。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.